Overview

We Are Kemin

We are visionaries who see things differently and are inspired by the world around us. We have been dedicated to using applied science to improve the quality of life for over half a century. Committed to feed and food safety, Kemin maintains top-of-the-line manufacturing facilities where over 500 specialty ingredients are made for humans and animals in the global feed and food industries, as well as the health, nutrition, and textile markets. We provide product solutions and options to customers in more than 120 countries.

A privately held, family-owned and operated company, Kemin has more than 3,000 global employees including manufacturing facilities in Belgium, Brazil, China, India, Italy, Russia, Singapore, South Africa and the United States.

#LI-KT1

Responsibilities

Responsible for all veterinary vaccines/biological product regulatory clearance & registration processes, including compilation of dossiers and ensuring accuracy and completeness of the same. Be accountable for progress & deadlines for assigned countries
Set up good regulatory network by establishing relationships with regulatory bodies in assigned countries
Stay vigilant and keep abreast of the regulatory changes (veterinary vaccines/biological product regulations)
Report on RA strategic plan monthly to RA Manager, participate in Kemin Biologics’ team tele-conference. Contribute to Kemin Worldwide RA network to ensure alignment of good practices and facilitate cross learning and sharing of information and resources.
Ensure regulatory compliance for all products and take preemptive actions to uphold the integrity and image of the company and its products. Supervise the generation and maintenance of product documentation such as specification sheets, Safety Data Sheets, product labeling, etc. and product mock-ups.
QA: assist in importation/batch release and GDP locally
PhV: implement the future PhV system in the responsible countries
Intellectual Property Management
- Adapt & implement WWIPRA’s policies in the assigned countries.
- Maintain & protect company confidential information (e.g. product formulas in the ERP system).
Participate in company driven projects.

Qualifications

Bachelor of Science or above, preferably in veterinary medicine, chemistry, or life science (e.g. agricultural science, food science, nutrition and etc.).
Minimum 4 years of experience in regulatory affairs of veterinary biological products.
Proven track record of accomplishments in getting veterinary biological product marketing authorizations in responsible countries.
Knowledge & skills in intellectual property management.
Possess good business acumen and customer orientated attitude, working experience in a commercial setting is an advantage.
Pleasant personality, good people skills. Good team spirit and team management skills.
Good project management skills.
Creative & resourceful in handling various regulatory barriers.
Communication skills - Ability to present ideas & suggestion effectively and communicate well with all levels of management in a multi-cultural environment.

About the company

Kemin is a global ingredient manufacturer that supplies more than 500 specialty ingredients for human health, food safety, and protecting the world’s food supply. It develops and delivers these ingredients for industries including animal health, nutraceuticals, pet food, crop technologies, aquaculture, textiles, and vaccines. It stands out as a privately held, family-owned company with a long history (founded in 1961) and a wide global footprint across 120+ countries, offering a diversified portfolio across multiple sectors. Its goal is to sustainably transform the quality of life for 80 percent of the world every day by improving health, safety, and the integrity of the food supply chain.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$115M

Headquarters

Des Moines, Iowa

Founded

1961

Get referred to Kemin

See people who can refer or advise you

Simplify's Take

What believers are saying

Singapore's EDB backed Kemin's US$35 million Kuriosity Centre on July 28, 2026.
April 2026 launches of EDIE Generation 2 and MEVAC MULTI ADENO broaden revenue.
September 2026 Avian Influenza Summit keeps Kemin central to poultry-biosecurity purchasing decisions.

What critics are saying

Church & Dwight challenged ENTEROSURE in TTAB on July 26, 2026.
AgroPlantae bought Kemin Crop Technologies, signaling pruning before growth stalls elsewhere.
Kemin depends on disease-driven animal-health demand; outbreak controls or vaccine failures crush momentum.

What makes Kemin unique

Kemin combines ingredients, animal vaccines, and applied science across 120 countries.
Its July 2026 Singapore Kuriosity Centre deepens regional R&D and customer collaboration.
Kemin Biologics sells genotype-matched poultry vaccines built for outbreak-specific field conditions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match
Paid Vacation
Paid Holidays
Wellness Program
Tuition Reimbursement
Training Programs

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

2 year growth

Feed and Additive

Sep 22nd, 2026

Kemin Biologics to bring global experts together for Avian Influenza Summit.

Kemin Biologics to bring global experts together for Avian Influenza Summit. 22 September 2026 Kemin Biologics will organize its fourth annual Avian Influenza Summit on October 15. The event will bring together experts from four regions to discuss emerging HPAI risks and disease-control strategies. Kemin Biologics, the vaccine business unit of Kemin Industries, will host its fourth annual virtual Avian Influenza Summit webinar on Thursday, October 15, at 13:00 Central European Time. The 90-minute Poultry World webinar will bring together leading independent experts from the Americas, Europe, Africa, and the Asia-Pacific region to discuss the emerging risks of highly pathogenic avian influenza (HPAI) and the latest strategies for managing these threats affecting poultry health, food security, and international public health. The 2026 summit comes as the continuing avian influenza panzootic presents significant challenges to poultry production and disease-control programs worldwide. Changes in the ecology and spread of avian influenza, including unusual mortality among wild birds and a growing number of reported infections in mammals, are prompting renewed evaluation of existing prevention and control strategies. "The rapidly evolving nature of avian influenza requires the global poultry sector to continually reassess how it prevents, detects, and controls the disease," said Francisco Monsalve, Global Brand Manager, Kemin Biologics. "Through the 2026 Avian Influenza Summit, Kemin Biologics aims to facilitate a practical, science-led exchange of knowledge from across regions." Against this background, the summit will examine how science-based surveillance, effective government policies, integrated risk management, and vaccination can contribute to more sustainable avian influenza prevention and control. The program will also explore the distinct epidemiological and biological characteristics of clade 2.3.4.4b HPAI viruses and their relevance to poultry-producing regions. The event will be moderated by Dr. Maarten De Gussem, an international consultant based in Belgium. The independent expert panel will include: - Dr. David Swayne, Independent Veterinarian - United States - Prof. J.J. (Sjaak) de Wit, Royal GD - Netherlands - Dr. Mariette Ducatez, Institute for Agriculture, Food, and Environment, INRAE (National Research Institute for Agriculture, Food and Environment) - France - Dr. Dennis Umali, University of the Philippines Los Baños - Philippines Drawing on experience from multiple poultry-producing regions, the speakers will discuss: - Emerging avian influenza virus clades and their potential implications for poultry production and public health - Government policies and integrated risk-management approaches - Vaccination best practices to support sustainable disease prevention and control - Regional lessons relevant to the evolving global HPAI situation According to the company, the summit forms part of Kemin Biologics' educational series and reflects the business unit's commitment to delivering knowledge and solutions that support effective disease management and a reliable food supply.

Kemin Industries

Aug 11th, 2026

Kemin Biologics Holds 2026 Respiratory Integrity Forum Highlighting Emerging Newcastle Disease Genotype VII

Kemin Biologics holds 2026 Respiratory Integrity Forum highlighting emerging Newcastle Disease Genotype VII. Event demonstrates Kemin's vaccine business unit's expertise and solutions for one of the poultry industry's most pressing challenges ROTTERDAM, Netherlands (August 11, 2026) - Kemin Biologics, the vaccine business unit of Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services by 2042, recently hosted the 2026 Respiratory Integrity Forum, a scientific exchange focused on one of the poultry industry's most pressing challenges: emerging Newcastle Disease Virus (NDV) Genotype VII. Kemin Biologics held the third session of the event - moderated by Poultry World - in Rotterdam, Netherlands, on June 9, and highlighted how collaboration, applied science, and practical field experience can help support stronger respiratory health strategies for producers worldwide. Kemin Biologics presented its NDV homologous vaccine solutions designed to support early protection against respiratory and enteric challenges associated with NDV Genotype VII. The NDV homologous vaccine solutions feature: * Genotype-matched protection against circulating NDV Genotype VII strains * Significant reduction in viral shedding to help limit transmission * A flexible vaccine range combining live and inactivated solutions for more comprehensive immunity over time The forum also featured respected voices in poultry health, including Professor Kannan Ganapathy of the University of Liverpool and Dr. Abdallah Makahleh, Global Technical Services Manager, Kemin Biologics. The speakers' perspectives reinforced the value of combining academic expertise with real-world field insight to address evolving disease threats and improve vaccination decision-making across poultry industry segments. The third session of the Respiratory Integrity Forum demonstrated Kemin Biologics' continued commitment to advancing poultry health through innovation, partnership, and vaccination best practices. By bringing together global insights and practical solutions, the 2026 Respiratory Integrity Forum reflected Kemin Biologics' role in helping the industry navigate complex Newcastle Disease challenges with confidence, credibility, and a strong focus on producer needs. About Kemin Industries Kemin Industries (www.kemin.com) is a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services. The company supplies over 500 specialty ingredients for human and animal health and nutrition, pet food, aquaculture, nutraceutical, food technologies, textile, biofuel, and animal vaccine industries. For over half a century, Kemin has been dedicated to using applied science to address industry challenges and offer product solutions to customers in more than 120 countries. Kemin provides ingredients to feed a growing population with its commitment to the quality, safety, and efficacy of food, feed, and health-related products. Established in 1961, Kemin is a privately held, family-owned-and-operated company with more than 4,000 global employees and operations in 90 countries, including manufacturing facilities in Belgium, Brazil, China, Egypt, India, Italy, Singapore, South Africa, and the United States. Media Contact: Francisco Monsalve, Global Brand Manager, Kemin Biologics | [email protected], +49 4722 909 4445 Kemin Biologics engaged a global audience to address emerging NDV Genotype VII at the 2026 Respiratory Integrity Forum.

Feed Strategy

Jul 30th, 2026

Kemin breaks ground on Kuriosity Centre in Singapore.

Kemin breaks ground on Kuriosity Centre in Singapore. US$35 million facility will expand Kemin's Asia-Pacific headquarters. July 30, 2026 Joyce Wong (JTC Corporation), Hong Yi (JTC Corporation), Christine Wong (JTC Corporation), Dr. Tan Hai Meng (Kemin), Dr. Chris Nelson (Kemin), Kelly Lai (Singapore Economic Development Board), Mei Chun Fong (Singapore Economic Development Board), Naoki Yoneyama (SMCC), and Richard Vergara (SMCC) participate in the foundation-laying ceremony for the Kuriosity Centre. Kemin Industries held a foundation-laying ceremony for its Kuriosity Centre, a $35 million flagship facility at its Singapore regional headquarters designed to expand innovation, collaboration, and customer capabilities across Asia-Pacific while accommodating over 140 employees. * Investment Size: Kemin is investing approximately US$35 million in the Kuriosity Centre with support from Singapore's Economic Development Board * Facility Scale: The four-story facility spans 5,880 square meters with a gross floor area of approximately 9,685 square meters * Capacity: Designed to accommodate more than 140 employees and connect to Kemin's existing campus via covered bridge * Regional Legacy: Kemin has served the Asia-Pacific region for nearly 40 years, with Singapore operations established 33 years ago * Strategic Purpose: The center will integrate research, technical expertise, business operations, and customer-facing capabilities to drive innovation and strengthen collaboration across Asia-Pacific business units Kemin Industries held a foundation-laying ceremony for its Kuriosity Centre, a new flagship facility at its Asia-Pacific regional headquarters in Singapore. Representing an investment of approximately US$35 million and supported by the Singapore Economic Development Board (EDB), the four-story development marks the next phase of the company's growth in Asia-Pacific and, Kemin said, will expand its ability to serve customers, support employees and bring its regional capabilities closer together. The ceremony was officiated by Chris Nelson, Ph.D., president and CEO, Kemin Industries, and Tan Hai Meng, Ph.D., president, Kemin Animal Nutrition and Health - Asia-Pacific, together with senior representatives from EDB and JTC Corporation. "I'm thrilled to be establishing the Kuriosity Centre here at our regional headquarters in Singapore, as it demonstrates Kemin's commitment to our customers, our team, and this region," said Nelson. "Kemin has been serving the region for nearly 40 years, and 33 years ago, my parents, R.W. and Mary Nelson, broke ground in Singapore to establish our permanent presence. Today, we build on that legacy and lay a foundation for the future - a place where curiosity is translated into science, and science into practical solutions for the industries that protect the health and safety of people, pets, and production animals." Built to support Kemin's future needs, the Kuriosity Centre will span 5,880 square meters with a proposed gross floor area of approximately 9,685 square meters. Designed to accommodate more than 140 employees, the facility will connect to Kemin's existing campus via covered bridge. The company said the spaces are intended to bring together research, technical expertise, business operations and customer-facing capabilities, and to encourage cross-functional exchange, strengthen collaboration across Kemin's Asia-Pacific business units, support customer and business partner interactions, and create opportunities for innovation and employment in Singapore. "Kemin's decision to establish its Kuriosity Centre here will reinforce Singapore's capabilities as a leading hub for innovative feed and food solutions in Asia," said Lim Wey-Len, executive vice president, Singapore Economic Development Board. "The new facility will bring together the company's regional business functions and strengthen its pipeline of solutions for the animal nutrition and food technology industries across the region. We look forward to working with like-minded partners like Kemin to capture new growth opportunities in high-value specialty ingredients innovation." Kemin said bringing expertise, technology and collaboration into one location will create new opportunities to learn, innovate and deliver solutions to customers across the region, and that the Kuriosity Centre will support the development of talent and continued growth of the company in the region. "Kemin's expansion reflects the confidence that global companies have in Singapore as a trusted base for innovation, manufacturing, and regional leadership," said Christine Wong, assistant CEO, JTC. "Building on nearly four decades of operations here, the Kuriosity Centre marks the next chapter of Kemin's growth in Asia-Pacific. We are pleased to support Kemin's long-term journey and look forward to partnering with Kemin as it continues to develop new capabilities and deliver innovative solutions from Singapore to customers across the region." Kemin said the completed facility will support its continued growth and represent the next chapter of the company in Asia-Pacific. Unlock Personalized Content! Sign up and the recommendations below will be more personalized for you!

Kemin Industries

Jul 28th, 2026

Kemin Industries Holds Foundation-laying Ceremony for New Kuriosity Centre at Asia-Pacific Regional Headquarters in Singapore

Kemin Industries holds foundation-laying ceremony for new Kuriosity Centre at Asia-Pacific regional headquarters in Singapore. US$35 million, four-story facility to strengthen Kemin's capabilities and support company's growth in Asia-Pacific region SINGAPORE, July 28, 2026 /PRNewswire/ - Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services by 2042, held a foundation-laying ceremony for its Kuriosity Centre, a new flagship facility at its Asia-Pacific regional headquarters in Singapore. Representing an investment of approximately US$35 million and supported by the Singapore Economic Development Board (EDB), the four-story development marks the next phase of the company's growth in Asia-Pacific and will expand Kemin's ability to serve customers, support employees, and bring its regional capabilities closer together. The ceremony was officiated by Dr. Chris Nelson, President and CEO, Kemin Industries, and Dr. Tan Hai Meng, President, Kemin Animal Nutrition and Health - Asia-Pacific, together with senior representatives from EDB and JTC Corporation. "I'm thrilled to be establishing the Kuriosity Centre here at our regional headquarters in Singapore, as it demonstrates Kemin's commitment to our customers, our team, and this region," said Dr. Nelson. "Kemin has been serving the region for nearly 40 years, and 33 years ago, my parents, R.W. and Mary Nelson, broke ground in Singapore to establish our permanent presence. Today, we build on that legacy and lay a foundation for the future - a place where curiosity is translated into science, and science into practical solutions for the industries that protect the health and safety of people, pets, and production animals." Built to support Kemin's future needs, the Kuriosity Centre will span 5,880 square meters with a proposed gross floor area of approximately 9,685 square meters. Designed to accommodate more than 140 employees, the facility will connect to Kemin's existing campus via covered bridge, creating an integrated environment that brings together research, technical expertise, business operations, and customer-facing capabilities. Together, these spaces are designed to encourage cross-functional exchange, strengthen collaboration across Kemin's Asia-Pacific business units, support customer and business partner interactions, and create opportunities for innovation and employment in Singapore as Kemin continues to grow. "Kemin's decision to establish its Kuriosity Centre here will reinforce Singapore's capabilities as a leading hub for innovative feed and food solutions in Asia," said Lim Wey-Len, Executive Vice President, Singapore Economic Development Board. "The new facility will bring together the company's regional business functions and strengthen its pipeline of solutions for the animal nutrition and food technology industries across the region. We look forward to working with like-minded partners like Kemin to capture new growth opportunities in high-value specialty ingredients innovation." By bringing expertise, technology, and collaboration into one location, Kemin can create new opportunities to learn, innovate, and deliver solutions to customers across the region. With a strong platform for developing talent, the Kuriosity Centre will support the development of talent and continued growth of Kemin in the region. "Kemin's expansion reflects the confidence that global companies have in Singapore as a trusted base for innovation, manufacturing, and regional leadership," said Christine Wong, Assistant CEO, JTC. "Building on nearly four decades of operations here, the Kuriosity Centre marks the next chapter of Kemin's growth in Asia-Pacific. We are pleased to support Kemin's long-term journey and look forward to partnering with Kemin as it continues to develop new capabilities and deliver innovative solutions from Singapore to customers across the region." With the foundation laid for the Kuriosity Centre, the facility will support Kemin's continued growth and help shape the next chapter of the company in Asia-Pacific for years to come. About Kemin Industries Kemin Industries (www.kemin.com) is a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services. The company supplies over 500 specialty ingredients for human and animal health and nutrition, pet food, aquaculture, nutraceutical, food technologies, textile, biofuel, and animal vaccine industries. For over half a century, Kemin has been dedicated to using applied science to address industry challenges and offer product solutions to customers in more than 120 countries. Kemin provides ingredients to feed a growing population with its commitment to the quality, safety, and efficacy of food, feed, and health-related products. Established in 1961, Kemin is a privately held, family-owned-and-operated company with more than 4,000 global employees and operations in 90 countries, including manufacturing facilities in Belgium, Brazil, China, Egypt, India, Italy, Singapore, South Africa, and the United States. Media Contact: Jocelyn Leung, Associate Marcom Manager, Kemin Animal Nutrition and Health - Asia-Pacific | [email protected] SOURCE Kemin Industries

CropLife

Apr 18th, 2026

AgroPlantae to acquire Kemin Industries' portfolio of Crop Technologies products.

AgroPlantae to acquire Kemin Industries' portfolio of Crop Technologies products. AgroPlantae, which serves the plant nutrition specialties industry with innovative, sustainable solutions to help crops overcome biotic and abiotic challenges and to restore soil and plant vitality to ensure high crop yields, has acquired the product portfolio of Kemin Crop Technologies, which provides growers with premium botanical-based biopesticides, plant nutrition, and soil health solutions designed for specialty crops, greenhouse production, and real-world agronomic challenges. AgroPlantae President and CEO Angelo Paolucci founded the company in 2009 to address the real struggles of farmers worldwide who were facing poor soil and climate conditions. Since its founding 17 years ago, AgroPlantae has demonstrated its commitment to research and innovation and established itself as a partner to growers, working with them to anticipate and overcome the plant growth stressors impacting their crops' genetic potential. "Kemin's crop technologies products that harness the power of plants and the company's long history of science-backed innovations to protect the health and safety of the global food supply chain are an ideal addition to the AgroPlantae line of products," said Paolucci. "At AgroPlantae, we operate on the idea of 'nature with the intelligence of science,' and Kemin Crop Technologies' variety of high-quality solutions rooted in research align perfectly with our efforts to address plant problems from the soil to harvest." AgroPlantae will absorb the complete suite of Kemin Crop Technologies products - TetraCURB(TM) MAX, AlliCURB(TM) MAX, PathoCURB(TM), RevoCURB(TM), Romivex(TM) DIP, OmniCURB(TM), Valena(TM), and Valena(TM) FLOW - as part of the transaction. To ensure continuity and maintain the highest level of support for customers, Kemin Crop Technologies' sales managers will also become part of AgroPlantae while remaining in their current territories in service to current customers. "AgroPlantae shares our passion to create a better world for future generations by taking care of our planet now, and we are confident the AgroPlantae team will continue to nurture and strengthen our science-back solutions that use biological crop protection and novel-plant growth technologies to target the needs of growers in a sustainable way," said Dr. Chris Nelson, President and CEO, Kemin Industries. AgroPlantae and Kemin will work closely to ensure continuity of customer support and supply during the transition. In addition to Kemin Crop Technologies' sales managers moving to AgroPlantae, all of Kemin Crop Technologies' product formulations, specifications, manufacturing processes, and quality standards will remain the same, and regulatory approvals will continue without interruption. Subscribe today for. In today's complex and fast-paced crop production sector, the team at CROPLIFE keeps 21,000 agricultural retailers, distributors and their suppliers up to date on such decidedly 21st century issues as seed technology, biotechnology, precision agriculture, customer service and retention, and business management. See all author stories here.

Kemin

Regulatory Affairs Associate

About the job